Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases.
AuthorsSheen, Aali J
Irlam, Joely J
Guest, Ryan D
Sherlock, David J
Hawkins, Robert E
Gilham, David E
AffiliationCancer Research United Kingdom, Department of Medical Oncology, Paterson Institute for Cancer Research, University of Manchester, United Kingdom.
MetadataShow full item record
AbstractPURPOSE: The overall aim of this study was to develop a novel treatment for colorectal cancer based on the use of gene therapy. Genetic modification of T lymphocytes has been used to specifically target and kill tumor cell lines directly. To test the efficacy of this method with clinically relevant materials, this study investigated the potential of T lymphocytes derived from patients with advanced colorectal disease to target autologous primary tumor material. METHODS T lymphocytes isolated preoperatively were modified genetically with recombinant retroviruses encoding CD3zeta-based chimeric immune receptors and were tested for functional activity against freshly isolated autologous tumor cells harvested from hepatic colorectal metastases. RESULTS: Patient-derived T cells were successfully transduced, and chimeric immune receptor expression was confirmed. Carcinoembryonic antigen expression on freshly isolated colorectal tumor cells was also demonstrated by molecular and immunohistochemical techniques. T cells expressing the anticarcinoembryonic antigen receptor were specifically activated by coculture with disaggregated or intact, diced tumor, whereas control non-carcinoembryonic antigen-targeted T-cell populations failed to activate. CONCLUSIONS: These results indicate that gene-targeted primary T lymphocytes depict specific functional activity against autologous colorectal tumor cells. This evidence indicates that chimeric immune receptor-expressing T cells may be able to circumvent the mechanisms used by tumor cells to avoid immune cell activity in vivo. This study emphasizes the potential of this approach as a therapy for carcinoembryonic antigen-expressing primary colorectal tumor and its metastases.
CitationGene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. 2003, 46 (6):793-804 Dis. Colon Rectum
JournalDiseases of the Colon and Rectum
- A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.
- Authors: Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, Schmidt-Wolf IG, Abken H
- Issue date: 2006 Aug
- T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches.
- Authors: Sheen AJ, Sherlock DJ, Irlam J, Hawkins RE, Gilham DE
- Issue date: 2003 Apr 7
- Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors.
- Authors: Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, Lehane M, Hawkins RE
- Issue date: 2002 Mar-Apr
- Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor.
- Authors: Beecham EJ, Ortiz-Pujols S, Junghans RP
- Issue date: 2000 May-Jun
- Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA<sup>+</sup> Metastatic Colorectal Cancers.
- Authors: Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, Luo Y, Zhang Q, Liu L, Qin H, Liu W, Wu F, Chen W, Pan F, Zhang X, Bie P, Liang H, Pecher G, Qian C
- Issue date: 2017 May 3